Robert J. Bujarski
Net Worth
Last updated:
What is Robert J. Bujarski net worth?
The estimated net worth of Mr. Robert J. Bujarski is at least $15,197,928 as of 15 Oct 2024. He owns shares worth $357,928 as insider and has received compensation worth at least $14,840,000 in QuidelOrtho Corporation.
What is the salary of Robert J. Bujarski?
Mr. Robert J. Bujarski salary is $1,060,000 per year as Chief Operating Officer in QuidelOrtho Corporation.
How old is Robert J. Bujarski?
Mr. Robert J. Bujarski is 57 years old, born in 1968.
What stocks does Robert J. Bujarski currently own?
As insider, Mr. Robert J. Bujarski owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
QuidelOrtho Corporation (QDEL) | Chief Operating Officer | 13,383 | $26.75 | $357,928 |
What does QuidelOrtho Corporation do?
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Robert J. Bujarski insider trading
QuidelOrtho Corporation
Mr. Robert J. Bujarski has made 15 insider trades between 2011-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 110,704 units of QDEL stock on 15 Dec 2017. As of 15 Oct 2024 he still owns at least 13,383 units of QDEL stock.
QuidelOrtho key executives
QuidelOrtho Corporation executives and other stock owners filed with the SEC:
- Dr. Werner Kroll (68) Senior Vice President of R&D
- Mr. Douglas C. Bryant (67) Pres, Chief Executive Officer & Director
- Mr. Randall J. Steward (71) Chief Financial Officer
- Mr. Ratan S. Borkar (51) Senior Vice President of International Commercial Operations
- Mr. Robert J. Bujarski (57) Chief Operating Officer